25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Candel Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Candel Therapeutics Inc together

I guess you are interested in Candel Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Candel Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Candel Therapeutics Inc

I send you an email if I find something interesting about Candel Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Candel Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Candel Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.47
Expected worth in 1 year
$-1.65
How sure are you?
10.5%

+ What do you gain per year?

Total Gains per Share
$-1.18
Return On Investment
-26.6%

For what price can you sell your share?

Current Price per Share
$4.43
Expected price per share
$2.3 - $5.57
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Candel Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$4.43
Intrinsic Value Per Share
$-6.27 - $-7.12
Total Value Per Share
$-6.74 - $-7.59

2.2. Growth of Candel Therapeutics Inc (5 min.)




Is Candel Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$15.2m$35.2m-$36.9m-2,270.0%

How much money is Candel Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$13m-$3.8m-$9.2m-70.8%
Net Profit Margin-271.9%8,590.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Candel Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#886 / 949

Most Revenue
#506 / 949

Most Profit
#605 / 949

Most Efficient
#554 / 949
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Candel Therapeutics Inc?

Welcome investor! Candel Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Candel Therapeutics Inc.

First you should know what it really means to hold a share of Candel Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Candel Therapeutics Inc is $4.43. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Candel Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Candel Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.47. Based on the TTM, the Book Value Change Per Share is $-0.29 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Candel Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.33-7.4%-0.40-9.1%-0.25-5.5%-0.25-5.5%-0.25-5.5%
Usd Book Value Change Per Share-0.16-3.7%-0.29-6.7%-0.22-5.1%-0.02-0.6%-0.02-0.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.16-3.7%-0.29-6.7%-0.22-5.1%-0.02-0.6%-0.02-0.6%
Usd Price Per Share6.93-4.05-1.33-2.72-2.72-
Price to Earnings Ratio-5.28--2.55--1.51--2.02--2.02-
Price-to-Total Gains Ratio-42.58--16.86--6.77--27.12--27.12-
Price to Book Ratio-14.75--5.65-1.24--0.10--0.10-
Price-to-Total Gains Ratio-42.58--16.86--6.77--27.12--27.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.43
Number of shares225
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.29-0.02
Usd Total Gains Per Share-0.29-0.02
Gains per Quarter (225 shares)-66.30-5.56
Gains per Year (225 shares)-265.21-22.25
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-265-2750-22-32
20-530-5400-45-54
30-796-8050-67-76
40-1061-10700-89-98
50-1326-13350-111-120
60-1591-16000-134-142
70-1856-18650-156-164
80-2122-21300-178-186
90-2387-23950-200-208
100-2652-26600-223-230

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.018.00.05.3%1.018.00.05.3%1.018.00.05.3%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%2.014.03.010.5%2.014.03.010.5%2.014.03.010.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.019.00.0%0.00.019.00.0%0.00.019.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%2.014.03.010.5%2.014.03.010.5%2.014.03.010.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Candel Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.163-0.295+81%-0.224+38%-0.025-85%-0.025-85%
Book Value Per Share---0.470-0.050-89%1.087-143%0.557-184%0.557-184%
Current Ratio--1.1851.852-36%8.884-87%7.551-84%7.551-84%
Debt To Asset Ratio--1.7091.147+49%0.453+277%0.734+133%0.734+133%
Debt To Equity Ratio---1.623-100%0.695-100%0.630-100%0.630-100%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--204839215.000124291397.500+65%71105915.000+188%155956851.154+31%155956851.154+31%
Eps---0.328-0.402+23%-0.246-25%-0.246-25%-0.246-25%
Ev To Ebitda Ratio---5.165-2.615-49%-1.815-65%-4.186-19%-4.186-19%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.202-0.221+9%-0.265+31%-0.200-1%-0.200-1%
Free Cash Flow To Equity Per Share---0.151-0.204+35%-0.264+75%-0.014-91%-0.014-91%
Gross Profit Margin--1.0001.0020%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---7.124--------
Intrinsic Value_10Y_min---6.266--------
Intrinsic Value_1Y_max---0.933--------
Intrinsic Value_1Y_min---0.917--------
Intrinsic Value_3Y_max---2.637--------
Intrinsic Value_3Y_min---2.521--------
Intrinsic Value_5Y_max---4.139--------
Intrinsic Value_5Y_min---3.856--------
Market Cap143866465.000-56%225055215.000131363397.500+71%43192415.000+421%88247898.158+155%88247898.158+155%
Net Profit Margin----2.7190%85.903-100%-75.1970%-75.1970%
Operating Margin----2.5190%-65.3310%-115.1300%-115.1300%
Operating Ratio---2.565-100%67.419-100%125.591-100%125.591-100%
Pb Ratio-9.430+36%-14.751-5.654-62%1.238-1292%-0.095-99%-0.095-99%
Pe Ratio-3.378+36%-5.285-2.546-52%-1.514-71%-2.024-62%-2.024-62%
Price Per Share4.430-56%6.9304.045+71%1.330+421%2.717+155%2.717+155%
Price To Free Cash Flow Ratio-5.472+36%-8.560-4.948-42%-1.314-85%-3.119-64%-3.119-64%
Price To Total Gains Ratio-27.222+36%-42.584-16.859-60%-6.768-84%-27.116-36%-27.116-36%
Quick Ratio--1.0841.753-38%8.578-87%7.373-85%7.373-85%
Return On Assets---0.495-0.466-6%-0.078-84%-0.174-65%-0.174-65%
Return On Equity----0.5610%-0.2190%-0.1790%-0.1790%
Total Gains Per Share---0.163-0.295+81%-0.224+38%-0.025-85%-0.025-85%
Usd Book Value---15257000.000-1626250.000-89%35289750.000-143%18079210.526-184%18079210.526-184%
Usd Book Value Change Per Share---0.163-0.295+81%-0.224+38%-0.025-85%-0.025-85%
Usd Book Value Per Share---0.470-0.050-89%1.087-143%0.557-184%0.557-184%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.328-0.402+23%-0.246-25%-0.246-25%-0.246-25%
Usd Free Cash Flow---6573000.000-7172750.000+9%-8598250.000+31%-6486263.158-1%-6486263.158-1%
Usd Free Cash Flow Per Share---0.202-0.221+9%-0.265+31%-0.200-1%-0.200-1%
Usd Free Cash Flow To Equity Per Share---0.151-0.204+35%-0.264+75%-0.014-91%-0.014-91%
Usd Market Cap143866465.000-56%225055215.000131363397.500+71%43192415.000+421%88247898.158+155%88247898.158+155%
Usd Price Per Share4.430-56%6.9304.045+71%1.330+421%2.717+155%2.717+155%
Usd Profit---10646000.000-13049750.000+23%-3813000.000-64%-6424052.632-40%-6424052.632-40%
Usd Revenue---888000.000-100%7750.000-100%206526.316-100%206526.316-100%
Usd Total Gains Per Share---0.163-0.295+81%-0.224+38%-0.025-85%-0.025-85%
 EOD+2 -6MRQTTM+21 -12YOY+18 -155Y+9 -2410Y+9 -24

3.3 Fundamental Score

Let's check the fundamental score of Candel Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.378
Price to Book Ratio (EOD)Between0-1-9.430
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.084
Current Ratio (MRQ)Greater than11.185
Debt to Asset Ratio (MRQ)Less than11.709
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.495
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Candel Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.105
Ma 20Greater thanMa 504.524
Ma 50Greater thanMa 1005.443
Ma 100Greater thanMa 2005.806
OpenGreater thanClose4.650
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Candel Therapeutics Inc

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Fundamental data was last updated by Penke on 2024-12-05 14:53:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Candel Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Candel Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-271.9%+271.9%
TTM-271.9%YOY8,590.3%-8,862.2%
TTM-271.9%5Y-7,519.7%+7,247.8%
5Y-7,519.7%10Y-7,519.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--112.2%+112.2%
TTM-271.9%-221.4%-50.5%
YOY8,590.3%-210.0%+8,800.3%
5Y-7,519.7%-342.2%-7,177.5%
10Y-7,519.7%-464.5%-7,055.2%
4.3.1.2. Return on Assets

Shows how efficient Candel Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • -49.5% Return on Assets means that Candel Therapeutics Inc generated $-0.49 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Candel Therapeutics Inc:

  • The MRQ is -49.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -46.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-49.5%TTM-46.6%-2.9%
TTM-46.6%YOY-7.8%-38.8%
TTM-46.6%5Y-17.4%-29.2%
5Y-17.4%10Y-17.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-49.5%-11.3%-38.2%
TTM-46.6%-11.7%-34.9%
YOY-7.8%-11.3%+3.5%
5Y-17.4%-12.7%-4.7%
10Y-17.4%-14.1%-3.3%
4.3.1.3. Return on Equity

Shows how efficient Candel Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Candel Therapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Candel Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-56.1%+56.1%
TTM-56.1%YOY-21.9%-34.2%
TTM-56.1%5Y-17.9%-38.3%
5Y-17.9%10Y-17.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM-56.1%-15.9%-40.2%
YOY-21.9%-14.3%-7.6%
5Y-17.9%-18.5%+0.6%
10Y-17.9%-19.3%+1.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Candel Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Candel Therapeutics Inc is operating .

  • Measures how much profit Candel Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Candel Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-251.9%+251.9%
TTM-251.9%YOY-6,533.1%+6,281.2%
TTM-251.9%5Y-11,513.0%+11,261.1%
5Y-11,513.0%10Y-11,513.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--222.9%+222.9%
TTM-251.9%-310.7%+58.8%
YOY-6,533.1%-223.5%-6,309.6%
5Y-11,513.0%-387.1%-11,125.9%
10Y-11,513.0%-498.5%-11,014.5%
4.3.2.2. Operating Ratio

Measures how efficient Candel Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.565-2.565
TTM2.565YOY67.419-64.855
TTM2.5655Y125.591-123.026
5Y125.59110Y125.5910.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.465-2.465
TTM2.5653.253-0.688
YOY67.4193.298+64.121
5Y125.5914.788+120.803
10Y125.5916.494+119.097
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Candel Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Candel Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.18 means the company has $1.18 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 1.185. The company is just able to pay all its short-term debts.
  • The TTM is 1.852. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.185TTM1.852-0.667
TTM1.852YOY8.884-7.032
TTM1.8525Y7.551-5.699
5Y7.55110Y7.5510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1853.637-2.452
TTM1.8523.890-2.038
YOY8.8844.666+4.218
5Y7.5515.953+1.598
10Y7.5516.277+1.274
4.4.3.2. Quick Ratio

Measures if Candel Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.08 means the company can pay off $1.08 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 1.084. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.753. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.084TTM1.753-0.669
TTM1.753YOY8.578-6.825
TTM1.7535Y7.373-5.619
5Y7.37310Y7.3730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0843.086-2.002
TTM1.7533.451-1.698
YOY8.5784.456+4.122
5Y7.3735.931+1.442
10Y7.3736.436+0.937
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Candel Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Candel Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Candel Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.71 means that Candel Therapeutics Inc assets are financed with 170.9% credit (debt) and the remaining percentage (100% - 170.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 1.709. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.147. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.709TTM1.147+0.562
TTM1.147YOY0.453+0.694
TTM1.1475Y0.734+0.413
5Y0.73410Y0.7340.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7090.350+1.359
TTM1.1470.344+0.803
YOY0.4530.310+0.143
5Y0.7340.365+0.369
10Y0.7340.382+0.352
4.5.4.2. Debt to Equity Ratio

Measures if Candel Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Candel Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.623-1.623
TTM1.623YOY0.695+0.929
TTM1.6235Y0.630+0.994
5Y0.63010Y0.6300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.394-0.394
TTM1.6230.432+1.191
YOY0.6950.380+0.315
5Y0.6300.451+0.179
10Y0.6300.490+0.140
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Candel Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Candel Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -5.28 means the investor is paying $-5.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Candel Therapeutics Inc:

  • The EOD is -3.378. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.285. Based on the earnings, the company is expensive. -2
  • The TTM is -2.546. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.378MRQ-5.285+1.907
MRQ-5.285TTM-2.546-2.739
TTM-2.546YOY-1.514-1.032
TTM-2.5465Y-2.024-0.522
5Y-2.02410Y-2.0240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.378-2.253-1.125
MRQ-5.285-2.411-2.874
TTM-2.546-3.149+0.603
YOY-1.514-3.274+1.760
5Y-2.024-6.143+4.119
10Y-2.024-6.785+4.761
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Candel Therapeutics Inc:

  • The EOD is -5.472. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.560. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.948. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.472MRQ-8.560+3.088
MRQ-8.560TTM-4.948-3.612
TTM-4.948YOY-1.314-3.633
TTM-4.9485Y-3.119-1.828
5Y-3.11910Y-3.1190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.472-3.009-2.463
MRQ-8.560-3.259-5.301
TTM-4.948-3.730-1.218
YOY-1.314-4.574+3.260
5Y-3.119-8.371+5.252
10Y-3.119-9.287+6.168
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Candel Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -14.75 means the investor is paying $-14.75 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Candel Therapeutics Inc:

  • The EOD is -9.430. Based on the equity, the company is expensive. -2
  • The MRQ is -14.751. Based on the equity, the company is expensive. -2
  • The TTM is -5.654. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.430MRQ-14.751+5.321
MRQ-14.751TTM-5.654-9.097
TTM-5.654YOY1.238-6.892
TTM-5.6545Y-0.095-5.558
5Y-0.09510Y-0.0950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.4301.979-11.409
MRQ-14.7512.051-16.802
TTM-5.6542.365-8.019
YOY1.2382.455-1.217
5Y-0.0953.726-3.821
10Y-0.0954.378-4.473
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Candel Therapeutics Inc.

4.8.1. Institutions holding Candel Therapeutics Inc

Institutions are holding 22.534% of the shares of Candel Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Northpond Ventures, LLC5.95930.7174193521500
2024-09-30Vanguard Group Inc2.91380.000194626512771515.6026
2024-06-30BlackRock Inc2.53440.00018230717754911629.8676
2024-09-30State Street Corp1.5150.0001492005192074.0624
2024-09-30Geode Capital Management, LLC1.38260.00034489975111112.8456
2024-09-30Sands Capital Ventures, LLC1.24970.790540583700
2024-09-30Halter Ferguson Financial Inc0.93771.12363045393045390
2024-09-30Northern Trust Corp0.48890.0002158771115326265.4529
2024-09-30Susquehanna International Group, LLP0.41710.00021354551354550
2024-09-30Bridgeway Capital Management, LLC0.24820.01218059500
2024-06-30MML Investors Services Inc0.22590.001873376733760
2024-09-30Nuveen Asset Management, LLC0.20390.000166217-315971-82.6742
2024-09-30Morgan Stanley - Brokerage Accounts0.19840644332551765.5694
2024-09-30HB Wealth Management, LLC0.17450.004256658566580
2024-06-30Bank of America Corp0.1677054449544490
2024-09-30Charles Schwab Investment Management Inc0.1440.00014677700
2024-09-30Bank of New York Mellon Corp0.13850.000144978-9471-17.3943
2024-09-30Goldman Sachs Group Inc0.09320302611203666.0412
2024-09-30Barclays PLC0.08830.00012868821971327.0954
2024-06-30Advisor Group Holdings, Inc.0.07940.000425800258000
Total 19.160232.65146222387+1473209+23.7%

4.9.2. Funds holding Candel Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-27iShares Russell 2000 ETF1.69560.0034550650-1148-0.208
2024-10-31Vanguard Total Stock Mkt Idx Inv1.6740.00025436428983219.7951
2024-03-31BANOR SICAV Rosemary S EUR Acc1.22812.366539882600
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr0.67770.001122007300
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.67250.0026218400-4100-1.8427
2024-08-31Fidelity Small Cap Index0.62720.005203680-5769-2.7544
2024-11-27iShares Russell 2000 Growth ETF0.55440.006718004900
2024-08-31Aesculape SRI IC0.4180.496113575000
2024-09-30Fidelity Extended Market Index0.3520.00191143282439727.1286
2024-09-30Vanguard US Momentum Factor ETF0.29940.100697216972160
2024-10-31State St Russell Sm Cap® Indx SL Cl I0.28610.00519290000
2024-10-31Vanguard Russell 2000 ETF0.27930.003990715-578-0.6331
2024-09-30Bridgeway Ultra-Small Company Market0.23060.29657489500
2024-09-30NT R2000 Index Fund - NL0.14930.005148481484810
2024-10-31Schwab Small Cap Index0.1440.00394677700
2024-11-27iShares Micro-Cap ETF0.13940.02254526900
2024-09-30NT R2000 Growth Index Fund - L0.13130.010142633426330
2024-09-30Northern Trust Russell 2000 Growth Index0.13130.010242633426330
2024-10-31iShares Russell 2000 Small-Cap Idx Instl0.12160.00433950600
2024-09-30Nuveen Equity Index R60.12090.000639266-226221-85.2098
Total 9.93273.34633225689+107376+3.3%

5.3. Insider Transactions

Insiders are holding 30.387% of the shares of Candel Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-29Seshu TyagarajanSELL203924.56
2024-11-29William Garrett NicholsSELL139354.56
2024-10-14Estuardo Aguilar-cordovaSELL150006.02
2024-10-11Estuardo Aguilar-cordovaSELL150006.05
2024-10-03Estuardo Aguilar-cordovaSELL18006.85
2024-07-17Charles SchochSELL98846.47
2024-07-17Paul Peter TakSELL225286.47
2024-07-17Seshu TyagarajanSELL148516.47
2024-07-11Charles SchochSELL88975.97
2024-07-11Paul Peter TakSELL202935.97
2024-07-11Seshu TyagarajanSELL133305.97
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets21,517
Total Liabilities36,774
Total Stockholder Equity-15,257
 As reported
Total Liabilities 36,774
Total Stockholder Equity+ -15,257
Total Assets = 21,517

Assets

Total Assets21,517
Total Current Assets18,085
Long-term Assets3,432
Total Current Assets
Cash And Cash Equivalents 16,558
Other Current Assets 1,527
Total Current Assets  (as reported)18,085
Total Current Assets  (calculated)18,085
+/-0
Long-term Assets
Property Plant Equipment 3,091
Long-term Assets Other 341
Long-term Assets  (as reported)3,432
Long-term Assets  (calculated)3,432
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities15,268
Long-term Liabilities21,506
Total Stockholder Equity-15,257
Total Current Liabilities
Short-term Debt 10,403
Accounts payable 296
Other Current Liabilities 4,569
Total Current Liabilities  (as reported)15,268
Total Current Liabilities  (calculated)15,268
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)21,506
Long-term Liabilities  (calculated)0
+/- 21,506
Total Stockholder Equity
Common Stock322
Retained Earnings -178,132
Other Stockholders Equity 162,553
Total Stockholder Equity (as reported)-15,257
Total Stockholder Equity (calculated)-15,257
+/-0
Other
Cash and Short Term Investments 16,558
Common Stock Shares Outstanding 32,014
Liabilities and Stockholders Equity 21,517
Net Debt -535
Net Working Capital 2,817
Short Long Term Debt Total 16,023



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
38,282
35,094
30,744
95,960
89,205
101,562
93,301
85,007
77,691
67,238
58,708
50,061
41,702
31,217
26,485
21,517
21,51726,48531,21741,70250,06158,70867,23877,69185,00793,301101,56289,20595,96030,74435,09438,282000
   > Total Current Assets 
0
0
0
35,146
29,471
24,426
90,950
84,945
95,646
87,326
79,070
71,945
61,875
53,362
45,101
36,797
27,136
22,735
18,085
18,08522,73527,13636,79745,10153,36261,87571,94579,07087,32695,64684,94590,95024,42629,47135,146000
       Cash And Cash Equivalents 
0
0
0
35,053
29,152
24,316
88,385
82,642
94,321
86,782
77,183
70,058
59,258
51,894
42,983
35,413
25,713
21,454
16,558
16,55821,45425,71335,41342,98351,89459,25870,05877,18386,78294,32182,64288,38524,31629,15235,053000
       Other Current Assets 
0
0
0
93
319
110
2,565
2,303
1,325
544
1,887
1,887
2,617
1,468
2,118
1,384
1,423
1,281
1,527
1,5271,2811,4231,3842,1181,4682,6171,8871,8875441,3252,3032,56511031993000
   > Long-term Assets 
0
0
0
3,136
5,623
6,318
5,010
4,260
5,916
5,975
5,937
5,746
5,363
5,346
4,960
4,905
4,081
3,750
3,432
3,4323,7504,0814,9054,9605,3465,3635,7465,9375,9755,9164,2605,0106,3185,6233,136000
       Property Plant Equipment 
0
0
0
2,787
4,263
4,606
4,587
3,836
5,479
5,709
5,671
5,480
5,097
4,921
4,555
4,022
3,713
3,403
3,091
3,0913,4033,7134,0224,5554,9215,0975,4805,6715,7095,4793,8364,5874,6064,2632,787000
       Other Assets 
0
0
0
0
1,360
1,712
423
424
437
266
266
266
0
425
0
0
0
0
0
0000042502662662664374244231,7121,3600000
> Total Liabilities 
0
0
0
61,844
62,591
73,919
32,973
25,068
37,800
33,229
32,880
29,977
27,586
27,937
27,039
28,957
25,238
36,457
36,774
36,77436,45725,23828,95727,03927,93727,58629,97732,88033,22937,80025,06832,97373,91962,59161,844000
   > Total Current Liabilities 
0
0
0
4,713
5,498
4,494
4,397
5,362
5,472
5,878
5,898
5,615
5,236
8,163
10,327
14,184
13,537
13,996
15,268
15,26813,99613,53714,18410,3278,1635,2365,6155,8985,8785,4725,3624,3974,4945,4984,713000
       Short-term Debt 
0
0
0
463
464
3,448
3,212
0
429
440
452
464
1,729
4,140
6,600
9,406
10,293
10,887
10,403
10,40310,88710,2939,4066,6004,1401,72946445244042903,2123,448464463000
       Short Long Term Debt 
0
0
0
463
464
0
0
0
0
0
0
0
1,253
3,652
6,100
8,893
9,767
9,809
0
09,8099,7678,8936,1003,6521,2530000000464463000
       Accounts payable 
0
0
0
921
1,513
759
925
1,590
1,386
1,584
970
380
592
480
250
422
472
433
296
2964334724222504805923809701,5841,3861,5909257591,513921000
       Other Current Liabilities 
0
0
0
187
223
224
229
3,772
3,657
3,854
4,476
4,627
2,783
3,423
3,369
4,356
2,772
2,676
4,569
4,5692,6762,7724,3563,3693,4232,7834,6274,4763,8543,6573,772229224223187000
   > Long-term Liabilities 
0
0
0
57,131
57,093
69,425
28,576
19,706
32,328
27,351
26,982
24,362
22,350
19,774
16,712
14,773
11,701
22,461
21,506
21,50622,46111,70114,77316,71219,77422,35024,36226,98227,35132,32819,70628,57669,42557,09357,131000
       Long term Debt Total 
0
0
0
0
0
521
541
560
20,525
20,630
0
0
19,697
0
0
0
0
0
0
00000019,6970020,63020,52556054152100000
       Warrants
0
0
0
0
0
49,060
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000049,06000000
       Other Liabilities 
0
0
0
0
7,531
19,844
28,035
19,146
9,965
4,996
4,626
2,026
0
1,134
0
0
0
0
0
000001,13402,0264,6264,9969,96519,14628,03519,8447,5310000
       Deferred Long Term Liability 
0
0
0
0
937
1,300
585
894
0
0
0
0
132
0
0
0
0
0
0
00000013200008945851,3009370000
> Total Stockholder Equity
0
0
0
-23,562
-27,497
-43,175
62,987
64,137
63,762
60,072
52,127
-99,089
39,652
30,771
23,022
12,745
5,979
-9,972
-15,257
-15,257-9,9725,97912,74523,02230,77139,652-99,08952,12760,07263,76264,13762,987-43,175-27,497-23,562000
   Common Stock
0
0
0
116
117
117
286
286
287
290
290
290
290
290
290
290
292
303
322
322303292290290290290290290290287286286117117116000
   Retained Earnings Total Equity000000-107,88400-85,318-81,169-80,295-81,891-65,72900000
   Accumulated Other Comprehensive Income 000000000000-95,960-26,560-1600000
   Capital Surplus 
0
0
0
0
0
22,437
144,592
144,146
144,644
145,548
0
0
147,694
0
0
0
0
0
0
000000147,69400145,548144,644144,146144,59222,43700000
   Treasury Stock000000-44800-448000000000
   Other Stockholders Equity 
0
0
0
20,493
21,195
22,437
144,592
144,146
144,644
145,100
145,843
-290
147,246
147,979
148,665
149,483
150,936
157,211
162,553
162,553157,211150,936149,483148,665147,979147,246-290145,843145,100144,644144,146144,59222,43721,19520,493000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue31
Cost of Revenue-23,980
Gross Profit-23,980-23,949
 
Operating Income (+$)
Gross Profit-23,980
Operating Expense-14,411
Operating Income-38,391-38,391
 
Operating Expense (+$)
Research Development24,506
Selling General Administrative13,724
Selling And Marketing Expenses687
Operating Expense14,41138,917
 
Net Interest Income (+$)
Interest Income2,081
Interest Expense-514
Other Finance Cost-1,597
Net Interest Income-30
 
Pretax Income (+$)
Operating Income-38,391
Net Interest Income-30
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-37,939-38,843
EBIT - interestExpense = -38,905
-37,939
-37,425
Interest Expense514
Earnings Before Interest and Taxes (EBIT)-38,391-37,425
Earnings Before Interest and Taxes (EBITDA)-37,431
 
After tax Income (+$)
Income Before Tax-37,939
Tax Provision-0
Net Income From Continuing Ops-31,927-37,939
Net Income-37,939
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses38,391
Total Other Income/Expenses Net45230
 

Technical Analysis of Candel Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Candel Therapeutics Inc. The general trend of Candel Therapeutics Inc is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Candel Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Candel Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.9 < 5.06 < 5.57.

The bearish price targets are: 3.785 > 3.06 > 2.3.

Tweet this
Candel Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Candel Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Candel Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Candel Therapeutics Inc. The current macd is -0.22282584.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Candel Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Candel Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Candel Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Candel Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCandel Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Candel Therapeutics Inc. The current adx is 19.70.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Candel Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Candel Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Candel Therapeutics Inc. The current sar is 4.23640466.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Candel Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Candel Therapeutics Inc. The current rsi is 42.11. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Candel Therapeutics Inc Daily Relative Strength Index (RSI) ChartCandel Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Candel Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Candel Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Candel Therapeutics Inc Daily Stochastic Oscillator ChartCandel Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Candel Therapeutics Inc. The current cci is -12.52865737.

Candel Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCandel Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Candel Therapeutics Inc. The current cmo is -13.09068774.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Candel Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCandel Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Candel Therapeutics Inc. The current willr is -63.86554622.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Candel Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Candel Therapeutics Inc Daily Williams %R ChartCandel Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Candel Therapeutics Inc.

Candel Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Candel Therapeutics Inc. The current atr is 0.42513423.

Candel Therapeutics Inc Daily Average True Range (ATR) ChartCandel Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Candel Therapeutics Inc. The current obv is 304,526,359.

Candel Therapeutics Inc Daily On-Balance Volume (OBV) ChartCandel Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Candel Therapeutics Inc. The current mfi is 61.61.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Candel Therapeutics Inc Daily Money Flow Index (MFI) ChartCandel Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Candel Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-16MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.

6.3. Candlestick Patterns

Candel Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Candel Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.105
Ma 20Greater thanMa 504.524
Ma 50Greater thanMa 1005.443
Ma 100Greater thanMa 2005.806
OpenGreater thanClose4.650
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Candel Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Candel Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Candel Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Candel Therapeutics Inc

I send you an email if I find something interesting about Candel Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Candel Therapeutics Inc.

Receive notifications about Candel Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.